Olatunde Olayanju1, Aliasgar Esmail1, Jason Limberis1, Phindile Gina1, Keertan Dheda2. 1. Centre for Lung Infection and Immunity Unit, Division of Pulmonology, Department of Medicine, University of Cape Town, South Africa. 2. Centre for Lung Infection and Immunity Unit, Division of Pulmonology, Department of Medicine, University of Cape Town, South Africa; Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: keertan.dheda@uct.ac.za.
Abstract
BACKGROUND: Treatment outcomes of patients with extensively drug-resistant tuberculosis (XDR-TB) are suboptimal and treatment options remain limited. Linezolid is associated with improved outcomes but also substantial toxicity, and details about the relationship between these are lacking from resource-poor HIV-endemic settings. METHODS: This was a prospective follow-up study of 63 South African XDR-TB patients (58.7% HIV-infected; median CD4 131 cells/μl) between 2014 and 2018. The frequency and severity of linezolid-associated adverse events and the impact on treatment outcomes were compared between linezolid interrupters and non-interrupters. RESULTS: Twenty-two patients (34.9%) discontinued or underwent dose reduction due to presumed linezolid-associated toxicity. Anaemia (77.3% vs. 7.3%; p< 0.001), peripheral neuropathy (63.6% vs. 14.6%; p= 0.003), and optic neuritis (18.2% vs. 9.8%; p= 0.34) occurred more frequently in linezolid interrupters than in non-interrupters. Anaemia, peripheral neuropathy, and optic neuritis occurred at a median of 5, 18, and 23 weeks, respectively, after treatment initiation. Linezolid interruption was not associated with unfavourable outcomes but was strongly associated with HIV co-infection (adjusted hazard ratio 4.831, 95% confidence interval 1.526-15.297; p= 0.007) and bacterial load (culture days to positivity; adjusted hazard ratio 0.824, 95% confidence interval 0.732- 0.927; p= 0.001). CONCLUSIONS: Linezolid-related treatment interruption is common, is strongly associated with HIV co-infection, and system-specific toxicity occurs within predictable time frames. These data inform the clinical management of patients with drug-resistant TB.
BACKGROUND: Treatment outcomes of patients with extensively drug-resistant tuberculosis (XDR-TB) are suboptimal and treatment options remain limited. Linezolid is associated with improved outcomes but also substantial toxicity, and details about the relationship between these are lacking from resource-poor HIV-endemic settings. METHODS: This was a prospective follow-up study of 63 South African XDR-TBpatients (58.7% HIV-infected; median CD4 131 cells/μl) between 2014 and 2018. The frequency and severity of linezolid-associated adverse events and the impact on treatment outcomes were compared between linezolid interrupters and non-interrupters. RESULTS: Twenty-two patients (34.9%) discontinued or underwent dose reduction due to presumed linezolid-associated toxicity. Anaemia (77.3% vs. 7.3%; p< 0.001), peripheral neuropathy (63.6% vs. 14.6%; p= 0.003), and optic neuritis (18.2% vs. 9.8%; p= 0.34) occurred more frequently in linezolid interrupters than in non-interrupters. Anaemia, peripheral neuropathy, and optic neuritis occurred at a median of 5, 18, and 23 weeks, respectively, after treatment initiation. Linezolid interruption was not associated with unfavourable outcomes but was strongly associated with HIV co-infection (adjusted hazard ratio 4.831, 95% confidence interval 1.526-15.297; p= 0.007) and bacterial load (culture days to positivity; adjusted hazard ratio 0.824, 95% confidence interval 0.732- 0.927; p= 0.001). CONCLUSIONS:Linezolid-related treatment interruption is common, is strongly associated with HIV co-infection, and system-specific toxicity occurs within predictable time frames. These data inform the clinical management of patients with drug-resistant TB.
Authors: L Mikiashvili; M Kipiani; M C Schechter; Z Avaliani; N Kiria; R R Kempker Journal: Int J Tuberc Lung Dis Date: 2020-04-01 Impact factor: 2.373
Authors: Mahmoud Tareq Abdelwahab; Sean Wasserman; James C M Brust; Keertan Dheda; Lubbe Wiesner; Neel R Gandhi; Robin M Warren; Frederick A Sirgel; Graeme Meintjes; Gary Maartens; Paolo Denti Journal: Antimicrob Agents Chemother Date: 2021-09-20 Impact factor: 5.191
Authors: Francesca Conradie; Tatevik R Bagdasaryan; Sergey Borisov; Pauline Howell; Lali Mikiashvili; Nosipho Ngubane; Anastasia Samoilova; Sergey Skornykova; Elena Tudor; Ebrahim Variava; Petr Yablonskiy; Daniel Everitt; Genevieve H Wills; Eugene Sun; Morounfolu Olugbosi; Erica Egizi; Mengchun Li; Alda Holsta; Juliano Timm; Anna Bateson; Angela M Crook; Stella M Fabiane; Robert Hunt; Timothy D McHugh; Conor D Tweed; Salah Foraida; Carl M Mendel; Melvin Spigelman Journal: N Engl J Med Date: 2022-09-01 Impact factor: 176.079
Authors: Afsatou Ndama Traoré; Mpumelelo Casper Rikhotso; Ntshuxeko Thelma Banda; Maphepele Sara Mashilo; Jean Pierre Kabue Ngandu; Vuyo Mavumengwana; Andre G Loxton; Craig Kinnear; Natasha Potgieter; Scott Heysell; Rob Warren Journal: Pathogens Date: 2022-06-01
Authors: Sean Wasserman; James C M Brust; Mahmoud T Abdelwahab; Francesca Little; Paolo Denti; Lubbe Wiesner; Neel R Gandhi; Graeme Meintjes; Gary Maartens Journal: J Antimicrob Chemother Date: 2022-03-31 Impact factor: 5.758
Authors: Gilbert Lazarus; Kevin Tjoa; Anthony William Brian Iskandar; Melva Louisa; Evans L Sagwa; Nesri Padayatchi; Vivian Soetikno Journal: PLoS One Date: 2021-03-04 Impact factor: 3.240